LAG3:FGL1[Biotinylated] Inhibitor Screening Assay Kit
The LAG3:FGL1[Biotinylated] Inhibitor Screening Assay Kit is designed to measure the binding of LAG3 (lymphocyte-activation gene 3) to FGL1 (fibrinogen-like protein 1) for screening and profiling applications. The LAG3:FGL1[Biotinylated] Inhibitor Screening Assay Kit comes in a convenient 96-well format, with enough recombinant purified biotinylated FGL1, LAG3 (amino acids 23-450), blocking and assay buffer and detection reagents for 100 enzyme reactions.
Need us to run inhibitor screens or profile your compounds against LAG3:FGL1[Biotinylated]? Check out our Immunotherapy Biochemical Screening Services.
- 1x PBS (phosphate buffer saline) Buffer
- PBST Buffer (1x PBS, containing 0.05% Tween-20)
- Luminometer or microplate reader capable of reading chemiluminescence
- Adjustable micropipettor and sterile tips
- Rotating or rocker platform
| Catalog # | Name | Amount | Storage |
| 71229 | LAG3, His-Tag* | 50 µg | -80°C |
| 100327 | FGL1, Fc-Fusion (IgG1), Avi-Tag, Biotin-Labeled | 5 µg | -80°C |
| 79311 | 3x Immuno Buffer 1 | 50 ml | -20°C |
| 79728 | Blocking Buffer 2 | 50 ml | +4°C |
| 79742 | Streptavidin-HRP | 10 µl | +4°C |
| 79670 | ELISA ECL Substrate A (translucent bottle) | 6 ml | Room Temp |
| ELISA ECL Substrate B (brown bottle) | 6 ml | Room Temp | |
| 79699 | 96-well white nickel coated microplate | 1 | Room Temp |
*The concentration of the protein is lot-specific and will be indicated on the tube.
LAG3 (lymphocyte-activation gene 3), also known as CD223, is a cell surface receptor that functions as an inhibitory immune checkpoint. It is found in CD4+ and CD8+ T cells, NK (natural killer) cells, NKT cells and Treg (T regulatory) cells. LAG3 is involved in T cell exhaustion and proliferation. It has several ligands, which include galectin-3, α-synuclein and Fibrinogen-like protein 1 (FGL1). LAG3 and FGL1 are found in tumor cells, where they can serve as immune checkpoints and potentially as oncogenes, and their levels correlate with patient prognosis. LAG3/FGL1 plays a role in immune cell function, cytokine production and tumor growth and metastasis. Several monoclonal antibodies targeting LAG3 are currently being tested, such as relatlimab, and have shown promising results alone or in combination therapy. Blockade of the FGL1-LAG3 interaction can promote antitumor immunity and may benefit patients that have developed tumor immune resistance. For instance, high levels of FGL1 may contribute to gefitinib therapy resistance while high LAG3 levels were found in patients after EGFR (epidermal growth factor receptor)-TKI (tyrosine kinase inhibitor) treatment. A deeper understanding of the importance of this complex in health and disease will allow the development of new cancer therapy strategies.
Wang J., et al., 2019 Immunol. 156.1: 74-85
Xu W., et al., 2018 Cell. Mol. Immunol. 15(5): 438
Shi A., et al., 2022 Front Immunol. 12:785091
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.